12:00 AM
Jun 17, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

DCP-001: Phase I/II data

An open-label, dose-escalation, Dutch Phase I/IIa trial in 12 elderly patients at high risk of relapse who were ineligible for post-remission therapy showed that DCP-001 given every 2 weeks for...

Read the full 130 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >